Skip to main content
HCPCS J7527 · Level II · Part B drug

J7527: everolimus (Zortress), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J7527

Billing unit
0.25 MG
Oral everolimus
ASP payment limit
$1.126
October 2026; -3.2% vs July 2026
Practitioner MUE
40
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J7527 is the Level II code for Everolimus, oral, 0.25 mg, billed per 0.25 MG. The Medicare Part B ASP payment limit for October 2026 is $1.126 per billing unit, down 3.2% from July 2026. The practitioner MUE allows up to 40 units per date of service (MAI 3), so a full 40-unit day is $45.04 at the current limit. Under OPPS it carries status indicator N. Oral drugs under Part B are payable only in the specific statutory categories (for example oral anticancer or antiemetic drugs with a self-administration exception), so the diagnosis and the regimen must match that category. The ASP crosswalk maps 27 NDCs to it, sold as Everolimus, Zortress by Hikma Pharmaceuticals USA Inc., Novartis Pharmaceuticals Corporation, Endo USA, Inc. No current Billing and Coding Article lists J7527, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J7527 at $1.126 per 0.25 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $1.163 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J7527
QuarterPayment limitPerCoinsurance
October 2026$1.1260.25 MG20%
July 2026$1.1630.25 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 27 NDCs from 6 labelers to J7527. Report the NDC in the claim's drug segment and bill the number of J7527 units that equals the quantity administered divided by 0.25 MG; the last column gives units per full package.

NDCs that crosswalk to J7527
NDCDrug nameLabelerPackage sizeBilling units / package
00054-0470-21EverolimusHikma Pharmaceuticals USA Inc.60 × 160
00054-0471-21EverolimusHikma Pharmaceuticals USA Inc.60 × 1120
00054-0472-21EverolimusHikma Pharmaceuticals USA Inc.60 × 1180
00078-0414-20ZortressNovartis Pharmaceuticals Corporation60 × 1120
00078-0415-20ZortressNovartis Pharmaceuticals Corporation60 × 1180
00078-0417-20ZortressNovartis Pharmaceuticals Corporation60 × 160
00078-0422-20ZortressNovartis Pharmaceuticals Corporation60 × 1240
49884-0158-02EverolimusEndo USA, Inc.60 × 160
49884-0159-02EverolimusEndo USA, Inc.60 × 1120
49884-0160-02EverolimusEndo USA, Inc.60 × 1180
49884-0283-02EverolimusEndo USA, Inc.60 × 1240
51991-0379-06EverolimusBreckenridge Pharmaceutical, Inc.60 × 160
51991-0379-60EverolimusBreckenridge Pharmaceutical, Inc.60 × 160
51991-0380-06EverolimusBreckenridge Pharmaceutical, Inc.60 × 1120
51991-0380-60EverolimusBreckenridge Pharmaceutical, Inc.60 × 1120
51991-0381-06EverolimusBreckenridge Pharmaceutical, Inc.60 × 1180
51991-0381-60EverolimusBreckenridge Pharmaceutical, Inc.60 × 1180
51991-0985-06EverolimusBreckenridge Pharmaceutical, Inc.60 × 1240
51991-0985-60EverolimusBreckenridge Pharmaceutical, Inc.60 × 1240
67877-0718-31EverolimusAscend Laboratories, LLC60 × 160
67877-0719-31EverolimusAscend Laboratories, LLC60 × 1120
67877-0720-31EverolimusAscend Laboratories, LLC60 × 1180
67877-0721-31EverolimusAscend Laboratories, LLC60 × 1240
70377-0069-11EverolimusBiocon Pharma Inc60 × 160
70377-0070-11EverolimusBiocon Pharma Inc60 × 1120
70377-0071-11EverolimusBiocon Pharma Inc60 × 1180
70377-0112-11EverolimusBiocon Pharma Inc60 × 1240

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J7527. For practitioners the limit is 40 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J7527 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services403 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital403 Date of Service Edit: ClinicalPrescribing Information
DME supplier9603 Date of Service Edit: ClinicalClinical: Data

MUE for J7527 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J7527 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J7527 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J7527 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J7527 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Local coverage policies that list J7527

1 active Local Coverage Determination lists J7527 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J7527 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J7527 carries payment indicator N1, which CMS defines as "Packaged service/item; no separate payment made". An N1 drug is packaged in the ASC: the facility receives no separate payment because the surgical procedure's rate already includes it.

Common denials for J7527 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J7527

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J7527

What does HCPCS code J7527 describe?

J7527 is defined by CMS as "Everolimus, oral, 0.25 mg". Each billing unit represents 0.25 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J7527 a CPT code?

No. J7527 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as everolimus (Zortress); CPT codes are five-character codes maintained by the AMA. On a Part B claim J7527 reports the drug itself in 0.25 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J7527 in October 2026?

The ASP-based payment limit is $1.126 per 0.25 MG, with 20% beneficiary coinsurance. The July 2026 limit was $1.163. Commercial payers use their own fee schedules.

How many units of J7527 can be billed per day?

The practitioner Medically Unlikely Edit is 40 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J7527?

The October 2026 ASP crosswalk lists 27 NDCs from 6 labelers: Everolimus (Hikma Pharmaceuticals USA Inc.); Zortress (Novartis Pharmaceuticals Corporation); Everolimus (Endo USA, Inc.); Everolimus (Breckenridge Pharmaceutical, Inc.). For example NDC 00054-0470-21 (package size 60) equals 60 billing units of J7527.

Does J7527 have NCCI bundling edits?

No active practitioner PTP pairs list J7527 as a column-1 or column-2 code in the v323r0 release.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.